Biosimilar Archives - Xtalks

Wednesday, August 12, 2026 | 11am EDT: Accelerate Cell Culture Media Development with Automated Cell Analysis

Kirsty, Biocon’s Insulin Aspart, Becomes First Interchangeable NovoLog Biosimilar in the US

Starjemza (Ustekinumab) FDA Approval: 2025’s First Biosimilar for Stelara in Psoriasis Care

Jobevne (Bevacizumab) Gains FDA Nod, Biocon Expands US Oncology Biosimilars Portfolio

Omlyclo Becomes First Biosimilar to Rival Xolair

Celltrion’s Steqeyma Approved as Stelara Biosimilar for Psoriasis

December 20, 2024

World Psoriasis Day 2024: New Treatments and Research Trends

October 24, 2024

FDA Approves Dong-A ST’s Imuldosa (Ustekinumab), a Stelara Biosimilar

October 16, 2024

Upstream Bioprocessing: DoE Optimization for CHO Cell Cultures

February 27, 2024

Innovations in Biosimilars: Insights and Trends from Samsung Bioepis

November 28, 2023

Interview with Dr. Gillian Woollett, VP, Head of Regulatory Strategy and Policy at Samsung Bioepis – Xtalks Life Science Podcast Ep. 110

Biosimilarity and Sameness Testing: Analytical Strategies to Fulfill FDA Submission Requirements

Idacio Approved as Eighth Adalimumab Biosimilar in the US

December 20, 2022

Riabni, the Biosimilar to Rituxan Gets FDA Approval for Rheumatoid Arthritis

Cyltezo Becomes First FDA-Approved Interchangeable Humira Biosimilar

October 22, 2021

Biosimilars vs. Interchangeable Biological Products: FDA Fact Check

February 8, 2021

Mylan’s Neulasta Biosimilar Looks to Grab Share of $4.2 Billion Market

Next Page »